| Literature DB >> 34136343 |
Pooja Bhattacharyya1,2, Andrew Bryan3, Vidya Atluri4, Jimmy Ma4, Lindsey Durowoju3, Anshu Bandhlish3, Jim Boonyaratanakornkit1,4.
Abstract
MRSA enterocolitis is under-recognized in the setting of PCR testing. In this case report, we describe risk factors, the importance of stool culture, and the third published case of MRSA enterocolitis in a patient with leukemia. In addition, we performed a retrospective analysis of all stool cultures at our institution that have grown Staphylococcus aureus, and we describe an additional five cases. We also report the diagnostic yield of organisms detected by culture, but not on the FilmArray panel. While rare, these cases demonstrate that MRSA in stool may indicate a severe and potentially life-threatening infection, particularly in immunocompromised persons.Entities:
Keywords: Enterocolitis; Immunocompromised; Staphylococcus aureus; Stool cultures
Year: 2021 PMID: 34136343 PMCID: PMC8178119 DOI: 10.1016/j.lrr.2021.100254
Source DB: PubMed Journal: Leuk Res Rep ISSN: 2213-0489
Fig. 1Clinical, microbiologic, radiographic, and histopathologic findings in a case of MRSA enterocolitis. (A) Timeline of the clinical course from diagnosis to death. (B) Stool cultures from a healthy individual (left) and from the patient (right) showing yellow colonies surrounded by hemolysis. (C) Antibiotic susceptibility testing of the Staphylococcus aureus isolate. (D) CT scan of the abdomen with the yellow arrow indicating an area of pneumatosis. (E) Postmortem histopathology of small bowel mucosa. The black arrow points to an area of Gram-positive cocci. The dotted arrow points to an area of submucosal necrosis and hemorrhage. Abbreviations: IV, intravenous; PO, oral; Vanc, vancomycin; Pip/tazo, piperacillin/tazobactam; MIC, minimum inhibitory concentration; AML, acute myeloid leukemia; CT, computed tomography; GCLAM, filgrastim, cladribine, cytarabine, and mitoxantrone; MIC, minimum inhibitory concentration; MRSA, methicillin resistant Staphylococcus aureus; TLS, tumor lysis syndrome.
Organisms recovered from blood agar, not detected by Biofire FilmArray (7/2018–6/2020).
| Organism group | N (%) | Comments |
|---|---|---|
| 30 (0.42%) | ||
| Not determined ( | ||
| 7 (0.10%) | ||
| Beta hemolytic streptococci | 4 (0.06%) | |
| 38 (0.53%) | ||
| 4 (0.06%) | ||
| 1 (0.01%) | ||
| Fungi | 112 (1.56%) | |
| Yeast ( |
Percent is out of N = 7179 total enteric panels performed.
Review of Staphylococcus aureus positive stool cultures from 1/2014–10/2020*.
| Age group (years) | Biofire | Discharge diagnosis by clinician | Comorbidities during diagnosis | Imaging | Antibiotics | Outcome |
|---|---|---|---|---|---|---|
| 5–10 | Norovirus | Norovirus | none | none | none | Outpatient |
| 20–29 | Negative | Laxative-induced | none | none | none | Outpatient |
| 30–39 | Negative | Neutropenic enterocolitis ( | Relapsed metastatic neuroblastoma status-post autologous hematopoietic stem cell transplant complicated by febrile neutropenia | CT: small bowel thickening | Vancomycin IV, cefepime IV, metronidazole IV | Discharged home with resolution |
| 30–39 | none | none | Azithromycin | Outpatient | ||
| 30–39 | Negative | Laxative-induced | Diabetic ketoacidosis, Staphylococcus aureus bacteremia complicated by epidural abscess and sepsis | none | Vancomycin IV | Discharged home with resolution |
| 50–59 | Negative | Neutropenic enterocolitis ( | Myelodysplastic syndrome status-post allogeneic hematopoietic stem cell transplant complicated by febrile neutropenia | CT: small bowel thickening | Vancomycin IV, cefepime IV, metronidazole IV | Discharged home with resolution |
| 70–79 | Negative | Neutropenic enterocolitis (attributed to | Acute myelogenous leukemia status-post induction chemotherapy complicated by febrile neutropenia, clinically quiescent Crohn's disease | CT: small bowel thickening and dilatation, pneumatosis | Piperacillin-tazobactam, vancomycin IV, vancomycin PO | Died of septic shock secondary to MRSA enterocolitis with severe neutropenia |
Cultures obtained at the University of Washington Medical Center and Seattle Cancer Care Alliance.